213Bi-7.16.4

213Bi-7.16.4 is a targeted radiopharmaceutical composed of the monoclonal antibody **7.16.4** conjugated to the alpha-particle emitting radionuclide **bismuth-213 (213Bi)**. The 7.16.4 antibody specifically binds to **rat HER-2/neu (Erbb2)** antigen, which is overexpressed in certain tumor types, notably some breast cancers. The mechanism of antitumor activity is via the emission of alpha particles from 213Bi, resulting in highly localized and potent cytotoxicity to targeted cancer cells. This agent has demonstrated the ability to induce specific cell kill of HER-2/neu positive tumor cells and spheroids in vitro, and to prolong survival and ablate metastases in preclinical mouse models of breast cancer. 213Bi-7.16.4 is investigated primarily as a targeted alpha therapy for cancer, where the antibody locates and binds HER-2/neu-expressing tumor cells and the radionuclide delivers lethal radiation selectively to those cells[2][4][10][8].

Other names

213Bi-labeled 7.16.4